Vladimir Limonnik, DO
Internal Medicine · Wynnewood, PANPI 1932697505
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,477 of the $5,411 with a category attached, or 64.3%. It is spread thinly across 43 manufacturers, the largest accounting for just 15.5%. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Partner Therapeutics, Inc.$837
- Seagen Inc.$592
- AstraZeneca$524
- Astellas Pharma US Inc$458
- Pfizer$252
- Lilly USA, LLC$231
- plus $3K from 37 others
What the payments were for
- Consulting fees$82515%
- Speaking & faculty fees$401%
- Food & beverage$3,47764%
- Education$1,06820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,411 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FulphilaPegfilgrastim-Jmdb | 18 | $39,348 |
| Anastrozole | 34 | $256 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wynnewood
- Bonnie GoldmannWynnewood$128K
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.